The drugmaker is halting production of Excedrin Extra Strength and Excedrin Migraine. A spokesperson told WSYR the halt is due to “inconsistencies in how we transfer and weigh ingredients for Excedrin Migraine caplets and geltabs.”
“Based on the available data, GSK believes that the product does not pose a safety risk to consumers. However, as a precautionary measure, GSK Consumer Healthcare has voluntarily implemented a discontinuation of production and distribution,” the spokesperson said.
The drugmaker said it does not know when it will resume production of the two drugs it’s halting, but other Excedrin products are available.
Some pharmacies in Central New York are already running out of the discontinued Excedrin products, WSYR reported.
Read the full article here.
More articles on pharmacy:
Walgreens, CVS demands led Ohio Medicaid to drop 272 pharmacies, state says
How Civica Rx became a force in the generic drug industry: A timeline
10 most expensive drugs for Medicare Part D
Walgreens, CVS demands led Ohio Medicaid to drop 272 pharmacies, state says
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
